Management of hematological malignancies in patients affected by renal failure

References

• Najman A, Andre K, Gorin NC. Influence of comorbidities on decision caring of malignant haematological diseases. Bull. Cancer96(5), 563–570 (2009).
   PubMed Web of Science ®Google Scholar
• Sorror M. Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. Biol. Blood Marrow Transplant.15(1 Suppl.), 149–153 (2009).
   PubMedGoogle Scholar
• Zhou Y, Tang Z, Liu ZH, Li LS. Acute lymphoblastic leukemia complicated by acute renal failure: a case report and review of the literature. Clin. Nephrol.73(4), 321–325 (2010).
   PubMed Web of Science ®Google Scholar
• Lahoti A, Kantarjian H, Salahudeen AK et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer116(17), 4063–4068 (2010).
   PubMed Web of Science ®Google Scholar
• Da’as N, Polliack A, Cohen Y et al. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur. J. Haematol.67(3), 158–164 (2001).
   PubMed Web of Science ®Google Scholar
• Ferreira AC, Brum S, Carvalho D et al. Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia. Hemodial. Int.14(1), 87–90 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen LJ, Rennke HG, Laubach JP, Humphreys BD. The spectrum of kidney involvement in lymphoma: a case report and review of the literature. Am. J. Kidney Dis.56(6), 1191–1196 (2010).
   PubMed Web of Science ®Google Scholar
• Markowitz GS. Dysproteinemia and the kidney. Adv. Anat. Pathol.11(1), 49–63 (2004).
   PubMed Web of Science ®Google Scholar
• Eleutherakis-Papaiakovou V, Bamias A, Gika D et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk. Lymphoma48, 337–341 (2007).
   PubMed Web of Science ®Google Scholar
• Heher EC, Goes NB, Spitzer TR et al. Kidney disease associated with plasma cell dyscrasias. Blood116(9), 1397–1404 (2010).
   PubMed Web of Science ®Google Scholar
• Woolfson RG. Paraproteins and the kidney. In: Cancer and the Kidney. Cohen PE (Ed.). Oxford University Press, Oxford, UK, 93–126 (2006).
   Google Scholar
• Dwyer JP, Yates KM, Sumner EL et al. Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. Clin. Nephrol.67(3), 176–181 (2007).
   PubMed Web of Science ®Google Scholar
• Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat. Rev. Nephrol.5(8), 450–462 (2009).
   PubMed Web of Science ®Google Scholar
• Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother. Pharmacol.63(4), 599–604 (2009).
   PubMed Web of Science ®Google Scholar
• Yarali N, Tavil B, Kara A, Ozkasap S, Tunç B. Acute renal failure during ATRA treatment. Pediatr. Hematol. Oncol.25(2), 115–118 (2008).
   PubMed Web of Science ®Google Scholar
• Ozkurt S, Temiz G, Acikalin MF, Soydan M. Acute renal failure under dasatinib therapy. Ren. Fail.32(1), 147–149 (2010).
   PubMed Web of Science ®Google Scholar
• Pou M, Saval N, Vera M et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk. Lymphoma44(7), 1239–1241 (2003).
   PubMed Web of Science ®Google Scholar
• Niscola P, Palumbo R, Scaramucci L et al. Membranous glomerulopathy as a late complication of chronic graft-versus-host disease following allogeneic stem cell transplantation: a concise review. Asia–Pacific J. Oncol. Hematol.1(2), 21–30 (2009).
   Google Scholar
• Ando M, Ohashi K, Akiyama H et al.Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol. Dial. Transplant.25(1), 278–282 (2010).
   PubMed Web of Science ®Google Scholar
• Tokgoz B, Kocyigit I, Polat G et al. Acute renal failure after myeloablative allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and relationship with the quantity of transplanted cells. Ren. Fail.32(5), 547–554 (2010).
   PubMed Web of Science ®Google Scholar
• Janus N, Launay-Vacher V, Byloos E et al. Cancer and renal insufficiency results of the BIRMA study. Br. J. Cancer103(12), 1815–1821 (2010).
   PubMed Web of Science ®Google Scholar
• Schupp N, Stopper H, Rutkowski P et al. Effect of different hemodialysis regimens on genomic damage in end-stage renal failure. Semin. Nephrol.26(1), 28–32 (2006).
   PubMed Web of Science ®Google Scholar
• Kinsella SM, Coyle JP, Long EB et al. Maintenance hemodialysis patients have high cumulative radiation exposure. Kidney Int.78(8), 789–793 (2010).
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. J. Am. Med. Assoc.298, 2038–2047 (2007).
   PubMed Web of Science ®Google Scholar
• de Francisco AL, De la Cruz JJ, Cases A et al. Prevalence of kidney insufficiency in primary care population in Spain: EROCAP study. Nefrologica27(3), 300–312 (2007).
   PubMed Web of Science ®Google Scholar
• Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist12(9), 1070–1083 (2007).
   PubMed Web of Science ®Google Scholar
• Boesler B, Czock D, Keller F et al. Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol. Dial. Transplant.20(6), 1187–1191 (2005).
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Oudard S, Janus N et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer110(6), 1376–1384 (2007).
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Spano JP, Janus N et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit. Rev. Oncol. Hematol.70(2), 124–133 (2009).
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Izzedine H, Rey JB et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med. Sci. Monit.10(5), CR209–CR212 (2004).
   PubMed Web of Science ®Google Scholar
• Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br. J. Haematol.122, 160–161 (2003).
   PubMed Web of Science ®Google Scholar
• Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk. Lymphoma49(6), 1108–1115 (2008).
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P. Renal failure associated with tyrosine kinase inhibitors – case report and review of the literature. Leuk. Res.34(1), 123–127 (2010).
   PubMed Web of Science ®Google Scholar
• Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin. J. Am. Soc. Nephrol.4(12), 2029–2034 (2009).
   PubMed Web of Science ®Google Scholar
• Bourquin V. Antibiotics dosing strategies in chronic kidney disease. Rev. Med. Suisse3(128), 2280–2288 (2007).
   PubMedGoogle Scholar
• Safdar A, Ma J, Saliba F et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore)89(4), 236–244 (2010).
   PubMed Web of Science ®Google Scholar
• Peyrière H, Jeziorsky E, Jalabert A et al. Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Ann. Pharmacother.40(1), 143–146 (2006).
   PubMed Web of Science ®Google Scholar
• Terpos E, Sezer O, Croucher PI et al. European Myeloma Network. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann. Oncol.20(8), 1303–1317 (2009).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol.28(33), 4976–4984 (2010).
   PubMed Web of Science ®Google Scholar
• Niscola P, Scaramucci L, Vischini G et al. The use of major analgesics in patients with renal dysfunction. Curr. Drug Targets11(6), 752–758 (2010).
   PubMed Web of Science ®Google Scholar
• Hassan Y, Al-Ramahi RJ, Aziz NA, Ghazali R. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann. Pharmacother.43(10), 1598–1605 (2009).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur. J. Cancer43(1), 14–34 (2007).
   PubMed Web of Science ®Google Scholar
• Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann. Oncol.21(7), 1395–1403 (2010).
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Chatelut E, Lichtman SM, Wildiers H, Steer C, Aapro M; International Society of Geriatric Oncology. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann. Oncol.18(8), 1314–1321 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr. Treat. Options Oncol.9(2–3), 191–203 (2008).
   PubMed Web of Science ®Google Scholar
• Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur. J. Clin. Pharmacol.65(8), 757–773 (2009).
   PubMed Web of Science ®Google Scholar
• Atkinson AJ Jr, Huang SM. Nephropharmacology: drugs and the kidney. Clin. Pharmacol. Ther.86(5), 453–456 (2009).
   PubMed Web of Science ®Google Scholar
• No authors listed. National Kidney Foundation (NFK). K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis.39(Suppl. 1), S1–S266 (2002).
   PubMed Web of Science ®Google Scholar
• Dong K, Quan DJ. Appropriately assessing renal function for drug dosing. Nephrol. Nurs. J.37(3), 304–308 (2010).
   PubMedGoogle Scholar
• Chang CH, Lin CY, Tian YC et al. Acute kidney injury classification: comparison of AKIN and RIFLE criteria. Shock33(3), 247–252 (2010).
   PubMed Web of Science ®Google Scholar
• Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br. J. Haematol.149(4), 578–586 (2010).
   PubMed Web of Science ®Google Scholar
• Haase R, Merkel N, Diwan O, Elsner K, Kramm CM. Leukapheresis and exchange transfusion in children with acute leukemia and hyperleukocytosis. A single center experience. Klin. Paediatr.221(6), 374–378 (2009).
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kapil N, Bhalla KN et al. Pharmacology and molecular mechanisms of antineoplastic agents for hematologic malignancies. In: Hematology, Basic Principles and Practice (Fifth Edition). Hoffman R, Benz EJ Jr, Shattil SJ et al. (Eds). Elsevier, Churchill Livingstone, PA, USA, 839–898 (2009).
   Google Scholar
• Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat. Rev.21(1), 33–64 (1995).
   PubMed Web of Science ®Google Scholar
• Aronoff GR, Bennett WM, Berns JS et al. Antineoplastic agents. In: Drug Prescribing in Renal Failure. Dosing Guidelines for Adults and Children (5th Edition). American College of Physicians, PA, USA, 169–175 (2007).
   Google Scholar
• de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet.44(11), 1135–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Carlson K, Hjorth M, Knudsen LM. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for dose adjustment. Br. J. Haematol.128, 631 (2005).
   PubMed Web of Science ®Google Scholar
• Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J. Clin. Oncol.15(2), 833–839 (1997).
   PubMed Web of Science ®Google Scholar
• Lindner LH, Ostermann H, Hiddemann W et al. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int. J. Hematol.88(4), 381–386 (2008).
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Etcubanas E, Budman DR et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest.20, 904 (2002).
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Stadler M, Czock D, Keller F, Hertenstein B, Radermacher J. Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. Eur. J. Haematol.74(6), 533–534 (2005).
   PubMed Web of Science ®Google Scholar
• Steinherz PG, Shukla N, Kobos R, Latcha S. Effect of hemodialysis on the plasma levels of clofarabine. Pediatr. Blood Cancer55(1), 196–198 (2010).
   PubMed Web of Science ®Google Scholar
• Crews KR, Wimmer PS, Hudson JQ, Howard SC, Ribeiro RC, Razzouk BI. Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J. Pediatr. Hematol. Oncol.24(8), 677–680 (2002).
   PubMed Web of Science ®Google Scholar
• Lathia C, Fleming GF, Meyer M et al. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother. Pharmacol.50(2), 121–126 (2002).
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist10(3), 176–182 (2005).
   PubMed Web of Science ®Google Scholar
• Tsao CF, Dalal J, Peters C, Gonzalez C, Kearns GL. Azacitidine pharmacokinetics in an adolescent patient with renal compromise. J. Pediatr. Hematol. Oncol.29(5), 330–333 (2007).
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Deray G. Thalidomide for the nephrologist. Nephrol. Dial. Transplant.20(9), 2011–2012 (2005).
   PubMedGoogle Scholar
• Niesvizky R, Naib T, Christos PJ et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Haematol.138, 640 (2007).
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol.47(12), 1466–1475 (2007).
   PubMed Web of Science ®Google Scholar
• Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother. Pharmacol.56(4), 358–360 (2005).
   PubMed Web of Science ®Google Scholar
• Ozdemir E, Koc Y, Kansu E. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am. J. Hematol.81(6), 474 (2006).
   PubMed Web of Science ®Google Scholar
• Gibbons J, Egorin MJ, Ramanathan RK et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J. Clin. Oncol.26(4), 570–576 (2008).
   PubMed Web of Science ®Google Scholar
• Sonmez M, Cobanoglu U, Ovali E, Omay SB. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. J. Clin. Pharm. Ther.33(3), 329–330 (2008).
   PubMed Web of Science ®Google Scholar
• Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr–Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk. Res.33(2), 344–347 (2009).
   PubMed Web of Science ®Google Scholar
• Mesquita Mdo C, Sol EB, Malarme M, Noubouossie D, Demulder AC. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. Clin. Ther.31(11), 2559–2564 (2009).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Takimoto C, Wood L et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother. Pharmacol.66(2), 345–356 (2010).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Sasaki M, Oshimi K, Sugimoto K. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia. Acta Haematol.122(1), 52–53 (2009).
   PubMed Web of Science ®Google Scholar
• Rajpurkar M, Alcasabas P, Warrier I et al. Effect of dialysis on all trans retinoic acid levels in a child with acute promyelocytic leukemia and renal failure. Pediatr. Blood Cancer49(7), 994–996 (2007).
   PubMed Web of Science ®Google Scholar
• Yamane A, Tsukamoto N, Saitoh T et al. Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Intern. Med.48(18), 1691–1694 (2009).
   PubMed Web of Science ®Google Scholar
• Morabito F, Gentile M, Ciolli S et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur. J. Haematol.84(3), 223–228 (2010).
   PubMed Web of Science ®Google Scholar
• Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am. J. Hematol.71(3), 219–222 (2002).
   PubMed Web of Science ®Google Scholar
• Ostronoff F, Ostronoff M, Florêncio R et al. Safety of fractionated dose of rituximab in renal failure patients receiving hemodialysis. Leuk. Lymphoma47(4), 757–759 (2006).
   PubMed Web of Science ®Google Scholar
• Greer JP, Foerster J, Rodgers GM et al. Wintrobe’s Clinical Hematology (12th Edition). Lippincott Williams & Wilkins, PA, USA (2008).
   Google Scholar
• Hoffman R, Benz EJ Jr, Shattil SJ et al. Hematology, Basic Principles and Practice (Fifth Edition). Elsevier, Churchill Livingstone, PA, USA (2009).
   Google Scholar
• Hoelzer D, Gokbuget N. Acute lymphocytic leukemia in the adults. In: Hematology, Basic Principles and Practice (5th Edition). Hoffman R, Benz EJ Jr, Shattil SJ et al. (Eds). Elsevier, Churchill Livingstone, PA, USA, 1003–1050 (2009).
   Google Scholar
• Eneman JD, Philips GK. Cancer management in patients with end-stage renal disease. Oncology (Williston Park)19(9), 1199–1212 (2005).
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Yamauchi T, Yoshida I et al. Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis. Int. J. Hematol.77, 196–198 (2003).
   PubMed Web of Science ®Google Scholar
• Feldmann G, Nattermann J, Gerhardt T, Nähle CP, Spengler U, Woitas R. Partial remission of a newly diagnosed diffuse large B-cell non-Hodgkin’s lymphoma in haemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. Int. J. Lab. Hematol.29(6), 469–473 (2007).
   PubMed Web of Science ®Google Scholar
• Poschl JM, Klaus G, Querfeld U et al. Chemotherapy with cytosine arabinoside in a child with Burkitt’s lymphoma on maintenance hemodialysis and hemofiltration. Ann. Hematol.67, 37–39, (1993).
   PubMed Web of Science ®Google Scholar
• Lin CJ, Chen HH, Hsieh RK, Chen YC, Wu CJ. Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma. Med. Oncol.26(1), 93–95 (2009).
   PubMed Web of Science ®Google Scholar
• Niscola P, Palumbo R, Scaramucci L et al. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis. Cancer Chemother. Pharmacol.63(4), 759–760 (2009).
   PubMed Web of Science ®Google Scholar
• Qian Q, Leung N, Theis JD, Dogan A, Sethi S. Coexistence of myeloma cast nephropathy, light chain deposition disease, and nonamyloid fibrils in a patient with multiple myeloma. Am. J. Kidney Dis.56(5), 971–976 (2010).
   PubMed Web of Science ®Google Scholar
• Grünfeld JP. Systemic diseases: from amyloidosis to cryoglobulinemia. Clin. J. Am. Soc. Nephrol.5(11), 1912–1915 (2010).
   PubMedGoogle Scholar
• Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim. Biophys. Acta1753(1), 11–22 (2005).
   PubMed Web of Science ®Google Scholar
• Bergesio F, Ciciani AM, Manganaro M et al.; Immunopathology Group of the Italian Society of Nephrology. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol. Dial. Transplant.23(3), 941–951 (2008).
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Reid S et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J. Am. Soc. Nephrol.18(3), 886–895 (2007).
   PubMed Web of Science ®Google Scholar
• Niscola P, Scaramucci L, Romani C et al. Pain management in multiple myeloma. Expert Rev. Anticancer Ther.10(3), 415–425 (2010).
   PubMed Web of Science ®Google Scholar
• Parikh GC, Amjad AI, Saliba RM et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol. Blood Marrow Transplant.15(7), 812–816 (2009).
   PubMed Web of Science ®Google Scholar
• Raab MS, Breitkreutz I, Hundemer M et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica91(11), 1555–1558 (2006).
   PubMed Web of Science ®Google Scholar
• Roussou M, Kastritis E, Christoulas D et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk. Res.34(10), 1395–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Zojer N. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat. Rev. Clin. Oncol.7(5), 289–294 (2010).
   PubMed Web of Science ®Google Scholar
• Mezzano SA, Barría M, Droguett MA et al. Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int.60(4), 1366–1377 (2001).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia22(2), 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica94(8), 1044–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood110(2), 787–788 (2007).
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr. Opin. Oncol.23(2), 214–120 (2011).
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J. Clin. Oncol.28(6), 1031–1037 (2010).
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Zeldenrust SR et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood109, 465–470 (2007).
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Perlini S et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood105, 2949–2951 (2005).
   PubMed Web of Science ®Google Scholar
• Pinto V, Castelli A, Gaidano G, Conconi A. Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure. Am. J. Hematol.85(6), 461–462 (2010).
   PubMed Web of Science ®Google Scholar
• Niscola P, Scaramucci L, Giovannini M et al. Palifermin in the management of mucositis in hematological malignancies: current evidences and future perspectives. Cardiovasc. Hematol. Agents Med. Chem.7(4), 305–312 (2009).
   PubMedGoogle Scholar
• Tendas A, Cupelli L, Dentamaro T et al. Feasibility of a dose-adjusted fludarabine–melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma. Ann. Hematol.88(3), 285–286 (2009).
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Stern M, Apperley J et al. The EBMT risk score predicts outcome after allogeneic HSCT in all haematological disease categories and is independent of stem cell source or conditioning intensity. Bone Marrow Transplant.41, S3 (2008).
   Google Scholar
• Bischoff ME, Blau W, Wagner T et al. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplant.22(6), 591–593 (1998).
   PubMed Web of Science ®Google Scholar
• Perry JJ, Fleming RA, Rocco MV et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant.23(8), 839–842 (1999).
   PubMed Web of Science ®Google Scholar
• Hamaki T, Katori H, Kami M et al. Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. Bone Marrow Transplant.30(3), 195–198 (2002).
   PubMed Web of Science ®Google Scholar
• Alfred A, Throssel D, Ezaydi Y, Jones B, Reilly JY, Snowden JA. Succesful myeloablative allogenic haemopoietic stem cell transplantation in a patients with end-stage renal failure on haemodialysis. Bone Marrow Transplant.37, S350 (2006) (Abstract 1199).
   Google Scholar
• de Souza JA, Saliba RM, Patah P et al. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.15(9), 1094–1099 (2009).
   PubMed Web of Science ®Google Scholar
• Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure. Clin. Lymphoma Myeloma8(1), 44–51 (2008).
   PubMedGoogle Scholar
• Dieterle F, Marrer E, Suzuki E, Grenet O, Cordier A, Vonderscher J. Monitoring kidney safety in drug development: emerging technologies and their implications. Curr. Opin. Drug Discov. Devel.11(1), 60–71 (2008).
   PubMed Web of Science ®Google Scholar